NCT04150913 2025-11-25A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated NeurotoxicityMassachusetts General HospitalPhase 2 Completed15 enrolled 17 charts
NCT05108805 2025-03-27Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient SettingVanderbilt-Ingram Cancer CenterPhase 4 Completed25 enrolled 17 charts
NCT04432506 2025-01-28Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell LymphomaM.D. Anderson Cancer CenterPhase 2 Completed22 enrolled 15 charts